These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31848295)

  • 1. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
    Chang LS; Oblinger JL; Burns SS; Huang J; Anderson LW; Hollingshead MG; Shen R; Pan L; Agarwal G; Ren Y; Roberts RD; O'Keefe BR; Kinghorn AD; Collins JM
    Mol Cancer Ther; 2020 Mar; 19(3):731-741. PubMed ID: 31848295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas.
    Oblinger JL; Wang J; Wetherell GD; Agarwal G; Wilson TA; Benson NR; Fenger JM; Fuchs JR; Kinghorn AD; Chang LS
    Sci Rep; 2024 Aug; 14(1):19349. PubMed ID: 39164287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
    Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
    Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor Effects of the eIF4A Inhibitor Didesmethylrocaglamide and Its Derivatives in Human and Canine Osteosarcomas.
    Oblinger J; Wang J; Wetherell G; Agarwal G; Wilson T; Benson N; Fenger J; Fuchs J; Kinghorn AD; Chang L
    Res Sq; 2024 Jun; ():. PubMed ID: 38947012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
    Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
    Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
    Butler E; Schwettmann B; Geboers S; Hao G; Kim J; Nham K; Sun X; Laetsch TW; Xu L; Williams NS; Skapek SX
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28639. PubMed ID: 32975370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7.
    Kim S; Hwang BY; Su BN; Chai H; Mi Q; Kinghorn AD; Wild R; Swanson SM
    Anticancer Res; 2007; 27(4B):2175-83. PubMed ID: 17695501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.
    Gampala S; Shah F; Zhang C; Rhodes SD; Babb O; Grimard M; Wireman RS; Rad E; Calver B; Bai RY; Staedtke V; Hulsey EL; Saadatzadeh MR; Pollok KE; Tong Y; Smith AE; Clapp DW; Tee AR; Kelley MR; Fishel ML
    Br J Cancer; 2021 Apr; 124(9):1566-1580. PubMed ID: 33658640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
    Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol.
    Cencic R; Carrier M; Galicia-Vázquez G; Bordeleau ME; Sukarieh R; Bourdeau A; Brem B; Teodoro JG; Greger H; Tremblay ML; Porco JA; Pelletier J
    PLoS One; 2009; 4(4):e5223. PubMed ID: 19401772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
    Kogure T; Kinghorn AD; Yan I; Bolon B; Lucas DM; Grever MR; Patel T
    PLoS One; 2013; 8(9):e76136. PubMed ID: 24086701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.
    Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A
    Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silvestrol induces early autophagy and apoptosis in human melanoma cells.
    Chen WL; Pan L; Kinghorn AD; Swanson SM; Burdette JE
    BMC Cancer; 2016 Jan; 16():17. PubMed ID: 26762417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species.
    Pan L; Woodard JL; Lucas DM; Fuchs JR; Kinghorn AD
    Nat Prod Rep; 2014 Jul; 31(7):924-39. PubMed ID: 24788392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic rocaglamide derivatives from Aglaia duppereana.
    El-Neketi M; Ebrahim W; Duong NT; Gedara S; Badria F; Saad HE; Müller WE; Proksch P
    Z Naturforsch C J Biosci; 2013; 68(7-8):269-74. PubMed ID: 24066511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines).
    Li-Weber M
    Int J Cancer; 2015 Oct; 137(8):1791-9. PubMed ID: 24895251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.
    Rodrigo CM; Cencic R; Roche SP; Pelletier J; Porco JA
    J Med Chem; 2012 Jan; 55(1):558-62. PubMed ID: 22128783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
    Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
    Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
    Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
    Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.